die Leute die nachdem PhaseII-Fail eingestiegen sind ein netter Gewinn ;-)
bin auch sehr gespannt, woher der Anstieg kommt, weil viel hat der Laden nicht zu bieten
Cash position: Cash and cash equivalents were $5,814,300 as of September 30, 2016, compared to $12,583,764 as of December 31, 2015. As of September 30, 2016, the Company had accounts payable and accrued expenses of $2,121,043.
Financial Guidance
Based on the current activities of the Company and projected burn, Opexa believes it has sufficient liquidity to support current activities in winding down the Abili-T trial and for general operations to sustain the Company and support such activities into the first quarter of 2017.
finance.yahoo.com/m/...1b4/ss_opexa-therapeutics%2C-inc..html